Our biotech pharma boom
Download
1 / 39

Pharma BOOM - PowerPoint PPT Presentation


  • 317 Views
  • Uploaded on

Our Biotech/Pharma BOOM. Dr H M Pang Senior consultant, HK UST Technology transfer June 2005, Shanghai,PRC. Booming statistics-West. 500 biotech companies employing >50K people, mostly established over the last 5 years genetically engineered products launched

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Pharma BOOM' - Donna


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Our biotech pharma boom l.jpg

Our Biotech/Pharma BOOM

Dr H M Pang

Senior consultant, HK UST

Technology transfer

June 2005, Shanghai,PRC


Booming statistics west l.jpg
Booming statistics-West

  • 500 biotech companies employing >50K people, mostly established over the last 5 years

  • genetically engineered products launched

  • >150 in clinical stages, more in preclinical

  • Many INDs filed since 1999 of bio origin

  • Sales increased by ~30%, profit 20%


Biotech boom china l.jpg
Biotech boom- China

  • Over 4 billion sales in 2004

  • Companies listing

  • Biopharma generics

  • A few new drugs ??

  • Drug spending increased 6 fold in 15 years

  • 5th ranking in 2010

  • 2nd ranking in 2020

  • …….. Lots of headache for now 


Biotech boom asia l.jpg
Biotech boom: Asia

  • Singapore’s massive investment getting results: MNC head quarters, R&D, export

  • Taiwan’s gradual strengthening of its bio tech on its strong pharma infra structure

  • Korea excellence in stem cell research

  • Hong Kong : direction unclear, good Unis.


Drivers of growth l.jpg
Drivers of growth

  • Growing economy & healthcare expense

  • Huge and aging population

  • Internal market>>critical mass for drug

  • Maturing consumers

  • Hunger for new drugs

  • Cost advantages, + skilled work force

  • Returnees with excellent expertise,& drive

    Excellent universities

  • Post genomic applications

  • Regulatory, ethical and legal considerations: stem cell


Government commitment l.jpg
Government commitment

  • Science parks and clusters

  • Clear priority and focus areas

  • Technology innovation, and incentives

  • Respect for IP ? ….improving 

  • Modernizing SFDA

  • Quality of science, talent pool

  • Industrial players, and mega players

  • Funding : govt, VC, and other industries


Industry sub sectors l.jpg
Industry sub sectors

  • Bio pharma: DDS, gene therapy, biochips, diagnostics

  • TCM, and functional food

  • Agro biotech and transgenic animals

  • Stem cells, tissue engineering, and cloning

  • Plant bio

  • Medical device and bio reagents


Focus areas l.jpg
Focus areas

  • DDS / chemical drugs

  • Stem cell and clinical applications

  • Bio protein drugs: recombinant technology

  • Medical devices, and genetic screening

  • GMP upgrade

  • GLP/GCP upgrade

  • APIs


Achievements l.jpg
Achievements

  • Centre for r&D, pre/clinical studies (dog)

  • Contract r&D centre for MNC’s & small cos.

  • Creation of clusters and science parks

  • Stem cell banks and application

  • Approval of engineered human tissue

  • mAB facility

  • Export of biotech to India and Cuba

  • API and finish dosages for export


Cruel reality the truth l.jpg
Cruel reality: the truth

  • Few really success stories

  • No world class players, small sales in global terms

  • Below standard products

  • Me-too products only

  • Lack significant VCs

  • No window in equity market

  • General depression of the pharma industry

  • FDA under pressure from consumers and industry

  • Virtual companies need short term success to justify survival, coming to China

  • Major failures of big companies:FE and 999


Success stories l.jpg
Success stories: ???

  • Many biotech companies making losses

  • Few break even or small profit

  • No real players, no exciting news

  • No real export to sophisticated market

  • Why????????????????????????????

  • Gross underestimation of the Drug Development cycle, not ready for World


Development hurdles l.jpg
Development hurdles

  • No real significant stars

  • Fierce competition, price wars, tenders

  • Formulary control ( Good time over , soon )

  • IP issues still not clear

  • Poor healthcare infrastructure to justify investment and return, very few VCs

  • Short, cheap, and fast philosophy prevails

  • Lack ROBUSTNESS: quality and performance

  • Lack INNOVATION

  • Not SUSTAINABLE

  • Insignificance in world market sales

  • Social out cry for change in healthcare provision


Part 2 innovation new fishes l.jpg

Part 2: INNOVATION: new fishes

The HK Science Park Biotech initiatives ( attempt )


Hkstp bio road map l.jpg
HKSTP bio road map

  • Biomedical research output audit

  • SWOT analysis of criteria for

  • Cluster formation

  • Total technology management

  • Seasoned executives & entrepreneurs

  • Others: industry, regulatory, funding


Technology transfer biomedical research in hksar l.jpg
Technology transfer: Biomedical research in HKSAR

  • Basic questions:

  • 1. Innovation/knowledge: tradable?

  • 2. Tech transfer: definition and skills?

  • 3. Commercialization capability?

  • 4. Future?

Dr H M Pang, HKUST, March16,05


Value from cluster formation l.jpg
Value from Cluster Formation

Knowledge Creation

Technology Transfer

Patents &

Proof of Concept

Business Planning

Licences

Testing

Incubation/

Research Parks

Universities &

Research Institutions

Venture Capital

Public & Private

Job Creation

Funding

Conception

Formation

Industry R & D

Regulatory

Environment

Collaboration/

Partnerships

Industry

Maturity

Growth

Partnerships

Clinical Trials

M&A Activity

Regulatory

Economics

Approval

of Scale

IPOs

/gazelles

Product Pipeline

Labour Market

Clusters & Networks

Commercialisation



Hong kong and mainland china l.jpg
Hong Kong and Mainland China

BEIBeijing University

FUDFudan University, Shanghai

GUZGuangzhou University

MMGFirst Military Medical College, Guangzhou

PEKPeking Union Medical College

SHAShantou University

SJTShanghai Jiao Tong University

SYS Sun Yat Sen University, Guangzhou

THBTsing Hua University, Beijing

ZSGZhongshan University, Guangzhou



Basic conditions for a biotech cluster l.jpg
Basic Conditions for a Biotech Cluster

Upstream

Midstream

Downstream



Recommendations l.jpg
Recommendations

  • Organize a cluster

  • Introduce TTM

  • Proper funding : pre seed fund

  • Cooperation between Industry & Research

  • Regional cooperation

  • Further exploit CEPA, and clinical trial

  • Stimulate research

  • Draw up road map for implementation


Recommendation 2 improve total technology management l.jpg
Recommendation 2Improve Total Technology Management


Technology transfer l.jpg
Technology transfer

  • Answers to questions:

  • 1. Innovation/knowledge: yes. Tradable?

  • 2. Tech transfer: to be re-modeled.

  • 3. Commercialization: can be done!

  • 4. Future: lets TALK………

  • Dr H M Pang , HKUST, March16,05


Part 3 commercialization l.jpg
Part 3: commercialization

  • Find the fish

  • Catch the fish, irrespective of size

  • Grow that fish: live, multiply, and more

  • Return in the shortest time, cost; quick $$

  • Lack long term vision, diligence, and often ethics and professionalism

  • Result= poor robustness, quality and performance



Total tech management ttm l.jpg
Total Tech Management:TTM

  • Complex, lengthy process

  • Resource/talent intensive, integrated skills

  • Need pharma industry expertise

  • IP and legal management

  • Regulatory and clinical component

  • Market intelligence / post marketing skills

  • Supply and logistics management

  • Financial skills

  • Critical mass


The 2nd pharma revolution l.jpg
The 2nd pharma revolution

  • New products, technology and services

  • New market, customers, payment terms

  • New sales and marketing approaches

  • New team and culture

  • Entry into new horizon, with good players

  • Go international

  • Sustainable model


New challenges l.jpg
New challenges

  • Survival, M&A, consolidation

  • Formulary, Rx, and price control

  • IP and regulatory: who stole my cream

  • Product and technology

  • Core competency

  • Focus

  • sustainability

  • Dancing with capital, to finance upgrade


New business models l.jpg
New business models

  • Integrated company or core strength

  • Work with universities and institutions

  • Work with virtual co, contract out research

  • Collaboration with the west, virtual cos.

  • Collaboration with the West, medium size

  • MNCs

  • Develop new drugs, at huge cost / risks


Cases a zhangjiang co l.jpg
Cases : a Zhangjiang co.

  • Set up 1996

  • HK Gem board 2002

  • One diagnostic launched, contract selling

  • Quality issue, broke contract

  • Robustness???

  • Money being spent, no real revenue

  • Huge pipe line hype

  • Lack real execution plan


Case 2 a tcm company hk l.jpg
Case 2: a TCM company, HK

  • Run by famous professor from Canada

  • Gem listing in HK 2001

  • Lack operational and business acumen

  • Unreal forecast, lack execution experience

  • Picked gingko for formulation improvement

  • Burnt out and sold in 2004


Case 3 a local medium pharma l.jpg
Case 3: a local medium pharma

  • 800M Yuan sales

  • Vision to become top 5 in 10 years

  • International involvement, courted with

  • Many international companies from India and Europe

  • Product introduction slow,

  • Alliance never realized

  • Failed to capture chances from capital market

  • Lack clear mid term strategy, team and culture

  • Fire fight in current hostile market

  • Uncertainty with future, lack sense of urgency / fear

  • Just received substantial investment for growth

  • Towards a potential ‘world class’ company


Case 4 stem cell in south l.jpg
Case 4: stem cell in South

  • A few cases as basis for business plan

  • No clear strategy, direction, IP, team and financial models. Doing everything.

  • Obtained some finance , but insufficient for the expected burnt rate

  • Sustainability?


Case 5 biochip diagnostics l.jpg
Case 5: biochip diagnostics

  • Multi genetic assay for cancer

  • Well received by investors, and supported by insurance companies

  • Company run by non business professionals, and scientist engage in more than one company

  • Short term apparent success

  • Issues: robustness, validation and marketing


Key success factors l.jpg
Key success factors

  • Product: quality, robustness, IP

  • Market: user friendly, entry barrier

  • Team: integrated skills, international

  • Finance: good start up, and profit/loss

  • Strategic investors

  • Execution: timely, and correctly

  • Sustainable business model


Sustainable company l.jpg
Sustainable company

  • Not too dependent on Allah ( GOD )

  • Ready to face competition

  • Continuous favorable performance ( no blip)

  • Not affected by cycles

  • Good pipeline portfolio

  • Not dependent on one Hero, holistic & governance

  • Evergreen, stable, long term team , execution capability

  • Anticipation and Management of change

  • International link

  • Tomorrow driven



ad